Your session is about to expire
← Back to Search
Sequence A: VHX-896 then iloperidone for Schizophrenia
Phase 1
Waitlist Available
Research Sponsored by Vanda Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 days
Awards & highlights
No Placebo-Only Group
Summary
Study to compare the pharmacokinetics and pharmacodynamics of VHX-896 and iloperidone and evaluate the safety and tolerability of VHX-896 and iloperidone in patients with schizophrenia or bipolar I disorder under steady state conditions.
Eligible Conditions
- Schizophrenia
- Bipolar Disorder
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Bioequivalence between VHX-896 tablets relative to iloperidone tablets
Secondary study objectives
Assessment of safety and tolerability of VHX-896 and iloperidone
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Sequence B: Iloperidone then VHX-896Experimental Treatment1 Intervention
Group II: Sequence A: VHX-896 then iloperidoneExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Iloperidone and VHX-896
2021
Completed Phase 1
~30
VHX-896 and iloperidone
2021
Completed Phase 1
~30
Find a Location
Who is running the clinical trial?
Vanda PharmaceuticalsLead Sponsor
62 Previous Clinical Trials
19,406 Total Patients Enrolled
6 Trials studying Schizophrenia
1,470 Patients Enrolled for Schizophrenia
Share this study with friends
Copy Link
Messenger